Poolbeg Pharma CEO on POLB001 & GLP-1 trial plans
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington talked with Proactive about the company’s interim results and key clinical milestones....…
0,048€
41,18%
Echtzeit-Aktienkurs Poolbeg Pharma PLC
Bid:
Ask:
Nachrichten zur Poolbeg Pharma PLC Aktie
Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
…
Poolbeg Pharma hails progress in first half of the year
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) pointed out that it has a cash runway out into 2027 as it begins a "catalyst-rich…
Poolbeg Pharma CEO on active H1, POLB 001 & GLP-1 trial plans
…
Poolbeg Pharma kicks off POLB001 Phase 2a trial with specialist partner
…
Poolbeg Pharma shares rise on trial partnership
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) shares climbed as much as 20% in morning trading after the company secured a partner…
Poolbeg Pharma secures partner for POLB 001 trial and free supply of cancer drug
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) has lined up a specialist clinical trials partner and secured free supply of a key…
Form 8.5 (EPT/RI) - Poolbeg Pharma Plc
FORM 8.5 (EPT/RI)…
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION…
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…
Gilead backs proposed Poolbeg Pharmas proposed tie-up with HOOKIPA
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with…
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…
AIM weekly movers: Fusion Antibodies chart indicates rise and potential Poolbeg Pharma merger sparks share price drop
Jonathan Rowland increased his stake in fire suppression technology company Zenova Group (LON: ZED) to 7.8%. The share price rebounded…
AIM movers: Revolution Beauty settlement and potential Nasdaq merger for Poolbeg Pharma
Revolution Beauty (LON: REVB) has come to a confidential agreement with Chrysalis Investments (LON: CHRY) over the claims related to…
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…
Poolbeg Pharma rapidly developing as rare disease specialist says broker
Poolbeg Pharma PLC (AIM:POLB) is already well down the path of establishing a rare disease company, said broker Shore Capital. “Lead…
Poolbeg Pharma confirms US patent grant
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has been granted a full patent in the United States for its drug candidate POLB…
Poolbeg Pharma shares jump after announcing year of progress
Poolbeg Pharma has revealed a substantial year of progress in which the well-capitalised biopharmaceuticals company made strides forward in the…
Poolbeg Pharma agrees 12 month option over orphan drug with fast-track potential
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has inked an exclusive 12-month option agreement to acquire a phase III-ready treatment from Silk Road...…
Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug
…
Poolbeg Pharma moves a step closer to locking down IP protection for key asset
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the US Patent Office has issued a Notice of Allowance for its immunomodulator II…